search
Back to results

Prenatal Iron Supplements: Safety and Efficacy in Tanzania (MAL1)

Primary Purpose

Malaria, Anemia

Status
Completed
Phase
Not Applicable
Locations
Tanzania
Study Type
Interventional
Intervention
Iron
Placebo
Sponsored by
Harvard School of Public Health (HSPH)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Malaria focused on measuring Malaria, Iron, Pregnancy, Anemia, Birth Weight

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • at or before 27 weeks of gestation
  • primigravida or secundigravidae
  • not anemic (defined as Hb<8.5 g/dL)
  • not iron deficient (defined as serum ferritin <12 μg/L)
  • HIV-uninfected
  • intend to stay in Dar es Salaam until delivery and for at least six weeks thereafter.

Exclusion Criteria:

  • After 27 weeks gestation
  • not primigravida or secundigravidae
  • anemic
  • iron deficient
  • HIV-infected
  • High iron stores at baseline (i.e., serum ferritin >200 μg/L)
  • do not intend to stay in Dar es Salaam until delivery and for at least six weeks thereafter.

Sites / Locations

  • Muhimbili University of Health And Allied Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Iron

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Incidence of placental malaria
Placental infection status will be categorized as infected if there are asexual parasites in the placenta blood; not infected if the placental blood smear is negative; or status unknown if no placental smear is available.
Placental malaria parasite density
Placental malaria parasite density will be defined as number of parasites per μL of blood or 200 white blood cells; the latter will be converted to a count per μL of blood assuming a count of 8000 WBC/μL.
Infant birth weight
Continuous measurement
Maternal hemoglobin
Continuous measurement

Secondary Outcome Measures

Low birth weight
Low birth weight will be defined as birth weight less than 2500 grams.
Maternal malaria infection
Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear.
Maternal anemia
Anemia will be defined as hemoglobin less than 11 g/dl. Severe anemia will be defined as less than 8.5 g/dl.

Full Information

First Posted
April 30, 2010
Last Updated
April 22, 2015
Sponsor
Harvard School of Public Health (HSPH)
Collaborators
Muhimbili University of Health and Allied Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01119612
Brief Title
Prenatal Iron Supplements: Safety and Efficacy in Tanzania
Acronym
MAL1
Official Title
Prenatal Iron Supplements: Safety and Efficacy in Tanzania
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
May 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Harvard School of Public Health (HSPH)
Collaborators
Muhimbili University of Health and Allied Sciences

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine safety and efficacy of prenatal iron supplementation in an area of high malaria burden among women who are not anemic or iron deficient.
Detailed Description
Iron deficiency anemia and malaria are urgent public health problems in sub-Saharan Africa, including Tanzania. There is a paucity of good quality randomized trials assessing the safety and efficacy of iron supplementation in pregnancy, and its effects on perinatal health outcomes. Prenatal iron supplementation is recommended based on its demonstrated benefit in preventing and treating maternal anemia. There is limited data on the efficacy of iron supplementation on pregnancy outcomes, including birth weight. There are also concerns regarding the use of iron supplementation, particularly among non-anemic women. In particular, there is a lack of research on the safety and efficacy of prenatal iron supplementation in developing regions, characterized by extensive burden of iron deficiency, malaria, and other endemic infectious diseases. Evidence from randomized controlled trials is urgently needed to examine the safety and efficacy of iron supplements among pregnant women in malaria endemic regions, particularly among women who are not anemic. NOTE: The time frames listed for the maternal malaria and hemoglobin outcomes were updated on 4/22/15. This record initially indicated that maternal malaria anemia and hemoglobin would be measured at several specific time points throughout the study. Instead, maternal malaria was measured throughout pregnancy and hemoglobin was measured only at delivery. Due to an oversight, we did not update this record when this protocol change took effect at the start of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria, Anemia
Keywords
Malaria, Iron, Pregnancy, Anemia, Birth Weight

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1500 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Iron
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Iron
Intervention Description
Daily oral dose of 60 mg from enrollment until delivery
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Daily oral dose from enrollment until delivery
Primary Outcome Measure Information:
Title
Incidence of placental malaria
Description
Placental infection status will be categorized as infected if there are asexual parasites in the placenta blood; not infected if the placental blood smear is negative; or status unknown if no placental smear is available.
Time Frame
Delivery
Title
Placental malaria parasite density
Description
Placental malaria parasite density will be defined as number of parasites per μL of blood or 200 white blood cells; the latter will be converted to a count per μL of blood assuming a count of 8000 WBC/μL.
Time Frame
Delivery
Title
Infant birth weight
Description
Continuous measurement
Time Frame
Delivery
Title
Maternal hemoglobin
Description
Continuous measurement
Time Frame
Delivery
Secondary Outcome Measure Information:
Title
Low birth weight
Description
Low birth weight will be defined as birth weight less than 2500 grams.
Time Frame
Delivery
Title
Maternal malaria infection
Description
Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear.
Time Frame
During pregnancy
Title
Maternal anemia
Description
Anemia will be defined as hemoglobin less than 11 g/dl. Severe anemia will be defined as less than 8.5 g/dl.
Time Frame
Delivery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: at or before 27 weeks of gestation primigravida or secundigravidae not anemic (defined as Hb<8.5 g/dL) not iron deficient (defined as serum ferritin <12 μg/L) HIV-uninfected intend to stay in Dar es Salaam until delivery and for at least six weeks thereafter. Exclusion Criteria: After 27 weeks gestation not primigravida or secundigravidae anemic iron deficient HIV-infected High iron stores at baseline (i.e., serum ferritin >200 μg/L) do not intend to stay in Dar es Salaam until delivery and for at least six weeks thereafter.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wafaie W Fawzi, MD, DrPH
Organizational Affiliation
Harvard School of Public Health (HSPH)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zul Premji, MD, MSC, PhD
Organizational Affiliation
Muhimbili University of Health and Allied Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Muhimbili University of Health And Allied Sciences
City
Dar es Salaam
ZIP/Postal Code
PO BOX 65001
Country
Tanzania

12. IPD Sharing Statement

Citations:
PubMed Identifier
36344770
Citation
Abioye AI, Hughes MD, Sudfeld CR, Premji Z, Aboud S, Hamer DH, Roberts DJ, Duggan CP, Fawzi WW. The effect of iron supplementation on maternal iron deficiency anemia does not differ by baseline anemia type among Tanzanian pregnant women without severe iron deficiency anemia. Eur J Nutr. 2023 Mar;62(2):987-1001. doi: 10.1007/s00394-022-03029-0. Epub 2022 Nov 8.
Results Reference
derived
PubMed Identifier
35710384
Citation
Yang J, Wang M, Tobias DK, Rich-Edwards JW, Darling AM, Abioye AI, Pembe AB, Madzorera I, Fawzi WW. Gestational weight gain during the second and third trimesters and adverse pregnancy outcomes, results from a prospective pregnancy cohort in urban Tanzania. Reprod Health. 2022 Jun 16;19(1):140. doi: 10.1186/s12978-022-01441-7.
Results Reference
derived
PubMed Identifier
33546607
Citation
Yang J, Wang D, Darling AM, Liu E, Perumal N, Fawzi WW, Wang M. Methodological approaches to imputing early-pregnancy weight based on weight measures collected during pregnancy. BMC Med Res Methodol. 2021 Feb 5;21(1):24. doi: 10.1186/s12874-021-01210-3.
Results Reference
derived
PubMed Identifier
26280534
Citation
Etheredge AJ, Premji Z, Gunaratna NS, Abioye AI, Aboud S, Duggan C, Mongi R, Meloney L, Spiegelman D, Roberts D, Hamer DH, Fawzi WW. Iron Supplementation in Iron-Replete and Nonanemic Pregnant Women in Tanzania: A Randomized Clinical Trial. JAMA Pediatr. 2015 Oct;169(10):947-55. doi: 10.1001/jamapediatrics.2015.1480.
Results Reference
derived

Learn more about this trial

Prenatal Iron Supplements: Safety and Efficacy in Tanzania

We'll reach out to this number within 24 hrs